Angioid streaks, clinical course, complications, and current therapeutic management.

abstract：:[This corrects the article on p. 741 in vol. 14, PMID: 29719401.]. ...

journal_title：Therapeutics and clinical risk management

authors：

更新日期：2018-06-26 00:00:00

abstract：Background and aim:The aim of this study was to investigate the association between low-density lipoprotein cholesterol (LDL-C) and the development of severe acute pancreatitis (SAP). Patients and methods:A total of 674 patients with acute pancreatitis were enrolled. Non-linearity in the relationship between LDL-C and...

journal_title：Therapeutics and clinical risk management

authors： Hong W,Zimmer V,Stock S,Zippi M,Omoshoro-Jones JA,Zhou M

更新日期：2018-05-30 00:00:00

abstract：BACKGROUND:Influenza A H1N1 and H3N2 are two influenza waves that have been identified in past years. METHODS:Data from 77 inpatients from three tertiary hospitals were included and statistical analysis was performed in three different clusters. RESULTS:Thirty-four patients (44.2%) had respiratory distress upon admis...

journal_title：Therapeutics and clinical risk management

authors： Petridis D,Zarogoulidis P,Kallianos A,Kioumis I,Trakada G,Spyratos D,Papaiwannou A,Porpodis K,Huang H,Rapti A,Hohenforst-Schmidt W,Zarogoulidis K

更新日期：2014-02-07 00:00:00

abstract：:Hepatoid adenocarcinoma of the stomach (HAS) is a rare subgroup of gastric cancer (GC). Morphologically, this tumor exhibits both adenocarcinomatous and hepatocellular differentiation, and most tumors show immunohistochemical staining for alpha-fetoprotein (AFP) or elevated AFP serum levels. The diagnosis of HAS is fr...

journal_title：Therapeutics and clinical risk management

authors： Søreide JA

更新日期：2019-12-23 00:00:00

abstract：:Coronary and cerebrovascular atherothrombosis are the leading cause of mortality and morbidity worldwide. Novel antiplatelet agents have been established for the management of patients with clinically evident coronary atherothrombosis and are increasingly used in these patients. These agents, however, have shown limit...

journal_title：Therapeutics and clinical risk management

authors： Iannopollo G,Camporotondo R,De Ferrari GM,Leonardi S

更新日期：2014-05-02 00:00:00

abstract：:The introduction of TNFα blockers has revolutionized the treatment of ankylosing spondylitis (AS). The objectives of this review are to summarize the most up-to-date data on long-term efficacy and safety of infliximab in AS, with special emphasis on axial and extra-articular disease, predictors of response, and radiol...

journal_title：Therapeutics and clinical risk management

authors： Elalouf O,Elkayam O

更新日期：2015-11-19 00:00:00

abstract：:We present here the case of a 33-year-old Chinese female patient with synchronous double primary malignant tumors (chronic myeloid leukemia [CML] and classic Hodgkin lymphoma). This patient was admitted to our hospital because of bilateral cervical lymph node enlargement and recurrent fever for 2 weeks. The complete b...

journal_title：Therapeutics and clinical risk management

authors： Liu Z,Li S,Bai O

更新日期：2017-09-05 00:00:00

abstract：Purpose:To compare running suture (RS) and interrupted suture (IS) of vesicourethral anastomosis (VUA) during open retropubic radical prostatectomy (RRP) on early urinary continence and extravasation. Patients and Methods:Single center analysis of 211 patients who underwent RRP performed by a single surgeon during 200...

journal_title：Therapeutics and clinical risk management

authors： Köhler N,El-Bandar N,Maxeiner A,Ralla B,Miller K,Busch J,Friedersdorff F

更新日期：2020-12-23 00:00:00

abstract：:Paclitaxel is an anticancer agent effective for the treatment of breast, ovarian, lung, and head and neck cancer. Because of water insolubility, paclitaxel is formulated with the micelle-forming vehicle Cremophor EL to enhance drug solubility. However, the addition of Cremophor EL results in hypersensitivity reactions...

journal_title：Therapeutics and clinical risk management

authors： Scripture CD,Figg WD,Sparreboom A

更新日期：2005-06-01 00:00:00

abstract：:Procarbazine HCl is a 'nonclassical' oral alkylating anticancer agent that was first synthesized in the late 1950s. It has been used in the treatment of many cancers, but its main use is in the treatment of Hodgkin's lymphoma and brain tumors and, to a lesser extent, Non-Hodgkin's lymphoma and primary central nervous ...

journal_title：Therapeutics and clinical risk management

authors： Armand JP,Ribrag V,Harrousseau JL,Abrey L

更新日期：2007-06-01 00:00:00

abstract：BACKGROUND:Adverse drug reactions are important determinants of inpatient and outpatient morbidity. Thiocolchicoside is a semisynthetic derivate of naturally occurring colchicoside, which is largely used in humans as a centrally acting muscle relaxant. Epileptic seizures after thiocolchicoside intake have been reported...

journal_title：Therapeutics and clinical risk management

authors： Giavina-Bianchi P,Giavina-Bianchi M,Tanno LK,Ensina LF,Motta AA,Kalil J

更新日期：2009-06-01 00:00:00

abstract：:The Clinical Assessment Program and Teflaro(®) Utilization Registry (CAPTURE) is a multicenter study evaluating the clinical use of ceftaroline fosamil in patients with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infection. Data were collected between August 2011 and Februa...

journal_title：Therapeutics and clinical risk management

authors： Maggiore C,Vazquez JA,Guervil DJ,Ramani A,Jandourek A,Cole P,Friedland HD

更新日期：2015-04-02 00:00:00

abstract：:One of the most feared repercussions of type 2 diabetes mellitus is the risk of adverse cardiovascular outcomes. The current antidiabetic agents on the market have had difficulty in showing cardiovascular outcome improvement. The EMPA-REG OUTCOME trial studied the sodium-glucose cotransporter 2 inhibitor empagliflozin...

journal_title：Therapeutics and clinical risk management

authors： Sanon VP,Patel S,Sanon S,Rodriguez R,Pham SV,Chilton R

更新日期：2017-05-03 00:00:00

abstract：OBJECTIVES:The objective of this study is to mathematically evaluate the influence of multiple factors on implant stability quotient values in clinical practice. PATIENTS AND METHODS:Resonance frequency analysis was performed at T1 (measured immediately at the time of implant placement) and at T2 (measured before dent...

journal_title：Therapeutics and clinical risk management

authors： Huang H,Wismeijer D,Shao X,Wu G

更新日期：2016-10-11 00:00:00

abstract：Purpose:Postoperative urinary retention (POUR) is one of the most common complications following spinal anesthesia. Spinal anesthesia may influence urinary bladder function due to interruption of the micturition reflex. Urinary catheterization is the standard treatment of POUR. Urinary catheter insertion is an invasive...

journal_title：Therapeutics and clinical risk management

authors： Senapathi TGA,Wiryana M,Subagiartha IM,Suarjaya IPP,Widnyana IMG,Sutawan IBKJ,Jaya AAGPS,Thewidya A

更新日期：2018-09-11 00:00:00

abstract：:Preterm birth is the major cause of perinatal morbidity and mortality in the developed world, and spontaneous preterm labor is the commonest cause of preterm birth. Interventions to treat women in spontaneous preterm labor have not reduced the incidence of preterm births but this may be due to increased risk factors, ...

journal_title：Therapeutics and clinical risk management

authors： Sanu O,Lamont RF

更新日期：2010-04-26 00:00:00

abstract：Purpose:Videolaryngoscopy in nasotracheal intubation has been reported to be better than direct laryngoscopy. The most suitable type of videolaryngoscope remains unknown. This study aimed to compare two videolaryngoscopes (McGrath MAC and Pentax AWS) with a Macintosh laryngoscope during nasotracheal intubation. Method...

journal_title：Therapeutics and clinical risk management

authors： Chae YJ,Kim DH,Park EJ,Oh J,Yi IK

更新日期：2019-09-18 00:00:00

abstract：:Adoptive T-cell immunotherapy is a rapidly growing field and is shifting the paradigm of clinical cancer treatment. Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor T-cell therapy that was initially developed at the National Cancer Institute and has recently been commercially approved by the...

journal_title：Therapeutics and clinical risk management

authors： Jain MD,Bachmeier CA,Phuoc VH,Chavez JC

更新日期：2018-05-31 00:00:00

abstract：BACKGROUND:Pressure ulcers (PUs) in the sacral region can be a complication of surgical procedures performed in the lithotomy position. Previous reports have noted a difference between men and women in PU development related to the supine position, and body weight and body mass index (BMI) have been also described as k...

journal_title：Therapeutics and clinical risk management

authors： Mizuno J,Takahashi T

更新日期：2017-02-17 00:00:00

abstract：:The treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) positively changed since the introduction of anti-TNFα drugs. These treatments were shown to reduce the symptoms and signs of the diseases and improve the quality of life. However, a variable percentage of patients do not respond to anti-TNFα o...

journal_title：Therapeutics and clinical risk management

authors： Lubrano E,Perrotta FM

更新日期：2016-10-21 00:00:00

abstract：:Treatment of advanced, recurrent or persistent cervical cancer includes radiotherapy and chemotherapy. Radiation has been the primary treatment modality for locoregionally advanced cervical cancer. Concomitant systemic cisplatin chemotherapy and radiation have shown high response rates with improvements in durable rem...

journal_title：Therapeutics and clinical risk management

authors： Robati M,Holtz D,Dunton CJ

更新日期：2008-02-01 00:00:00

abstract：:The advent of exponential growth of novel agents tested and approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has brought about a need for understanding of the mechanism of action, side-effects, and clinical efficacy of these drugs as they relate to these patients. Thi...

journal_title：Therapeutics and clinical risk management

authors： Patel NK,Finianos A,Whitaker KD,Aragon-Ching JB

更新日期：2014-08-16 00:00:00

abstract：:Cetuximab is a monoclonal antibody able to inhibit and to degrade the transmembrane receptor Her-1, also known as epidermal growth factor receptor (EGFR). The inhibition of EGFR is of major importance since the receptor influences many important tumor cell activities including tumor growth, neo-angiogenesis, inhibitio...

journal_title：Therapeutics and clinical risk management

authors： Merlano M,Occelli M

更新日期：2007-10-01 00:00:00

abstract：PURPOSE:A meta-analysis was conducted to evaluate the clinical outcomes, complications, reoperation rates, and late neurological deterioration between anterior decompression and fusion (ADF) and laminoplasty (LAMP) in the treatment of multilevel cervical ossification of the posterior longitudinal ligament (OPLL). METH...

journal_title：Therapeutics and clinical risk management

authors： Liu W,Hu L,Chou PH,Liu M,Kan W,Wang J

更新日期：2016-04-26 00:00:00

abstract：:Experimental data indicate that several pharmacological agents that have long been used for the management of various diseases unrelated to cancer exhibit profound in vitro and in vivo anticancer activity. This is of major clinical importance, since it would possibly aid in reassessing the therapeutic use of currently...

journal_title：Therapeutics and clinical risk management

authors： Papanagnou P,Baltopoulos P,Tsironi M

更新日期：2015-05-18 00:00:00

abstract：:Sodium disorders are the most common and most poorly understood electrolyte disorders in neurological patients. The aim of this study was to determine the incidence of sodium disorders and its association with different traumatic brain injuries. This prospective study was conducted in 80 patients diagnosed with modera...

journal_title：Therapeutics and clinical risk management

authors： Paiva WS,Bezerra DA,Amorim RL,Figueiredo EG,Tavares WM,De Andrade AF,Teixeira MJ

更新日期：2011-01-01 00:00:00

abstract：:Chordomas are rare, locally aggressive skull base neoplasms known for local recurrence and not-infrequent treatment failure. Current evidence supports the role of maximal safe surgical resection. In addition to open skull-base approaches, the endoscopic endonasal approach to clival chordomas has been reported with fav...

journal_title：Therapeutics and clinical risk management

authors： Di Maio S,Yip S,Al Zhrani GA,Alotaibi FE,Al Turki A,Kong E,Rostomily RC

更新日期：2015-05-26 00:00:00

abstract：:COVID-19 pandemic is inducing acute respiratory distress syndrome, multi-organ failure, and eventual death. Respiratory failure is the leading cause of mortality in the elderly population with pre-existing medical conditions. This group is particularly vulnerable to infections due to a declined immune system, comorbid...

journal_title：Therapeutics and clinical risk management

authors： Rahman S,Singh K,Dhingra S,Charan J,Sharma P,Islam S,Jahan D,Iskandar K,Samad N,Haque M

更新日期：2020-10-20 00:00:00

abstract：:Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians. Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran. Idarucizumab was approved in 2015 by the...

journal_title：Therapeutics and clinical risk management

authors： Proietti M,Boriani G

更新日期：2018-08-22 00:00:00

abstract：:Some specific features of the 24 h blood pressure (BP) pattern are linked to the progressive injury of target tissues and the triggering of cardiac and cerebrovascular events. In particular, many studies show the extent of the nocturnal BP decline relative to the diurnal BP mean (the diurnal/nocturnal ratio, an index ...

journal_title：Therapeutics and clinical risk management

authors： Hermida RC,Ayala DE,Calvo C

更新日期：2007-03-01 00:00:00